Single- and repeated-dose pharmacokinetics of eplerenone, a selective aldosterone receptor blocker, in rats

References

• COOK, C. S. BERRY, L. M., KIM, D. H., BURTON, E. G., HRIBAR, J. D. and ZHANG, L., 2002, Involvement of CYP3A in the metabolism of eplerenone in humans and dogs: differential metabolism by CYP3A4 and CYP3A5. Drug Metabolism and Disposition, 30,1344–1351.
   PubMed Web of Science ®Google Scholar
• DE GASPARD, M., JOSS, U., RAMJOUE, P., WHITEBREAD, S. E., HAENNI, H., SCHENKEL, L., KRAEHENBUEHL, C., BIOLLAZI, M., GROB, J., SCHMIDLIN, J., WIELAND, P. and WEHRLI, H. U., 1986, Three new epoxy-spironolactone derivatives: characterization in vivo and in vitro. Journal of Pharmacology and Experimental Therapeutics, 240, 650–656.
   Google Scholar
• KATAYAMA, S., ABE, M. and Ism', J., 1994, Differential effects of angiotensin II and aldosterone on cardiovascular hypertrophy. Hypertension Research, 17, 233–237.
   Google Scholar
• MACFADYEN, R. J., BARR, C. S. and STRUTHERS, A. D., 1997, Aldosterone blockade reduces vascular collagen turnover, improves heart rate variability and reduces early morning rise in heart rate in heart failure patients. Cardiovascular Research, 35, 30–34.
   PubMed Web of Science ®Google Scholar
• MAZEL, P., 1972, General principles and procedures for drug metabolism in vitro. In B. N. La Du, H. G. Mandel and E. L. Way (eds), Fundamentals of Drug Metabolism and Drug Disposition (Baltimore: Williams & Wilkins), pp. 527–545.
   Google Scholar
• MCKELVIE, R. S., YUSUF, S., PERICAK, D., AVEZUM, A., BURNS, R. J., PROBSTFIELD, J., TSUYUKI, R. T., WHITE, M., ROULEAU, J., LATINI, R., MAGGIONI, A., YOUNG, J. and POGUE, J., 1999, Comparison of candesartan, enalapril, and their combination in congestive heart failure. Randomized Evaluation of Strategies for Left ventricular Dysfunction (RESOLVD) pilot study. Circulation, 100, 1056–1064.
   PubMed Web of Science ®Google Scholar
• OKITA, R. T., CLARK, J. E., OKITA, J. R. and MASTERS, B. S. S., 1991, (.0- and (co — 1)-hydroxylation of eicosanoids and fatty acids by high-performance liquid chromatography. In M. R. Waterman and E. F. Johnson (eds), Methods in Enzymology, Vol. 206 (San Diego: Academic Press), pp. 432–441.
   Google Scholar
• PACKER, M. and COHN, J. N., 1999, Consensus recommendations for the management of heart failure. American Journal of Cardiology, 83, 1A–38A.
   Google Scholar
• PETERSON, G. L., 1979, Review of the Folin phenol protein quantitation method of Lowry, Rosenbrough, Farr and Randall. Analytical Biochemistry, 100, 201–220.
   PubMed Web of Science ®Google Scholar
• PITT, B., 1995, 'Escape' of aldosterone production in patients with left ventricular dysfunction treated with an angiotensin converting enzyme inhibitor: implications for therapy. Cardiovascular Drugs and Therapy, 9, 145–149.
   PubMed Web of Science ®Google Scholar
• PITT, B., ZANNAD, F., REMME, W. J., CODY, R., CASTAIGNE, A., PEREZ, A., PALENSKY, J. and WITTES, J. for the Randomized Aldactone Evaluation Study Investigators, 1999, The effect of spironolactone on morbidity and mortality in patients with severe heart failure. New England Journal of Medicine, 341, 709–717.
   Google Scholar
• PLOPPER, C. B., WEIR, A. J., MORIN, D., CHANG A., PHILPOT, R. M. and BUCKPITT, A. R., 1993, Postnatal changes in the expression and distribution of pulmonary cytochrome P450 monooxygenases during Clara cell differentiation in rabbits. Molecular Pharmacology, 44, 51–61.
   Google Scholar
• SMITH, D. J. and GORDON, E. R., 1998, Role of liver plasma membrane fluidity on the pathogenesis of estrogen-induced cholestasis. Journal of Laboratory and Clinical Medicine, 112, 679–854.
   Google Scholar
• SONDERFAN, A. J., ARLOTTO, M. P., DUTTON, D. R., MCMILLEN, S. K. and PARKINSON, A., 1987, Regulation of testosterone hydroxylation by rat liver microsomal cytochrome P450. Archives of Biochemistry and Biophysics, 255, 27–41.
   PubMed Web of Science ®Google Scholar
• STAESSEN, J., LUNEN, P., FAGARD, R., VERSCHUEREN, L. J. and AMERY, A., 1981, Rise in plasma concentration of aldosterone during long-term angiotensin II suppression. Journal of Endocrinology, 91, 457–465.
   PubMed Web of Science ®Google Scholar
• STRUTHERS, A. D., 1995a, Aldosterone escape during ACE inhibitor therapy in chronic heart failure. European Heart Journal, 16(suppl. N), 103–106.
   Google Scholar
• STRUTHERS, A. D., 1995b, Mineralocorticoid receptor blockade in chronic heart failure. Journal of Human Hypertension, 9, 443–446.
   PubMed Web of Science ®Google Scholar
• THE CONSENSUS TRIAL STUDY GROUP, 1987, Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). New England Journal of Medicine, 316, 1429–1435.
   PubMed Web of Science ®Google Scholar
• THE SOLVD INVESTIGATORS, 1991, Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. New England Journal of Medicine, 325, 293–302.
   PubMed Web of Science ®Google Scholar
• THOMSON, T. N. and KLAASSEN, C. D., 1995, The effect of hepatic microsomal enzyme inducers on the pharmacokinetics of ouabain after portal and systemic administration to rats. Journal of Pharmacy and Pharmacology, 47, 1041–1047.
   PubMedGoogle Scholar
• WAXMAN, D. J., DANNAN, G. A. and GUENGRICH, F. P., 1985, Regulation of rat hepatic cytochrome P-450: age dependent expression hormonal imprinting, and xenobiotic inducibility of sex-specific isozymes. Biochemistry, 24, 4409–4417.
   PubMed Web of Science ®Google Scholar
• WEBER, K. T. and VILLAREAL, D., 1993, Role of aldosterone in congestive heart failure. Postgraduate Medicine, 93, 203–221.
   PubMed Web of Science ®Google Scholar
• YAMAZAKI, H. and SHIMADA, T., 1997, Progesterone and testosterone hydroxylation by cytochrome P450 2C9, 2C19 and 3A4 in human microsomes. Archives of Biochemistry and Biophysics, 346, 161–169.
   PubMed Web of Science ®Google Scholar